Non-small-cell lung cancer-associated gene mutations and inhibitors
Lung cancer is the second most common cancer worldwide with tobacco being the largest external cause of the disease. Lung cancer is broadly classified into Small Cell Lung Cancer (SCLC) and Non-small-cell Lung Cancer (NSCLC). Depending on the stage of lung cancer, various treatment approaches such a...
Main Authors: | Ashwini Kumar, Awanish Kumar |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-12-01
|
Series: | Advances in Cancer Biology - Metastasis |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2667394022000508 |
Similar Items
-
A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients
by: Xilin Hu, et al.
Published: (2023-06-01) -
Identification of nine mutant genes and establishment of three prediction models of organ tropism metastases of non‐small cell lung cancer
by: Shuchen Chen, et al.
Published: (2023-02-01) -
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
by: Kai Fu, et al.
Published: (2022-12-01) -
Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients
by: Obradovic Jasmina, et al.
Published: (2012-12-01) -
Mutation status analysis of 58 patients with advanced ALK fusion gene positive non small cell lung cancer
by: Yuan Yang, et al.
Published: (2023-09-01)